Key result
EHBP1 rs2710642GG genotype is linked to ~2.7-fold higher dyslipidemia risk in ESRD dialysis patients.
Why the study?
Mutations in the EHBP1 gene may influence lipid metabolism, but their association with dyslipidemia risk in dialysis patients with end-stage renal disease in the Chinese Han population was unclear.
Are EHBP1 SNPs associated with an increased risk of dyslipidemia in end-stage renal disease patients on dialysis?
Case-Control (n=539)
No
Are EHBP1 SNPs associated with an increased risk of dyslipidemia in end-stage renal disease patients on dialysis?
EHBP1 rs2710642G and rs2710642GG genotypes, along with their interactions with BMI and other SNPs, are associated with an increased risk of dyslipidemia in Chinese Han patients with end-stage renal disease on dialysis.
Should not yet change dyslipidemia management in dialysis; leaves open replication and outcome prediction in prospective cohorts.
Background Lipid metabolism is influenced by mutations in the EH domain binding protein 1 gene (EHBP1). This study investigated the link between the EHBP1 single-nucleotide polymorphisms (SNPs) and dyslipidemia risks in maintenance dialysis patients with end-stage renal disease in Chinese Han population. Methods A total of 539 patients were divided into dyslipidemia (379) and control (160) groups. The patients with dyslipidemia were divided into four subgroups: high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol (HDLC), high triglyceride (TG) and high total cholesterol groups. The genotype distributions of three EHBP1 SNPs (rs2710642, rs10496099 and rs1168816) were determined by high-throughput sequencing technology and were analyzed via generalized multifactor dimension reduction and binary logistic regression analysis. Results The high-TG and control groups differed in terms of the genotype frequency of the rs2710642. One haplotype was detected in both the dyslipidemia and high-TG groups. The risk of dyslipidemia was 2.72-fold higher in participants with rs2710642GG compared with those of rs2710642AA and 2.62-fold higher compared with those with rs2710642AA + GA. Subjects who carried rs2710642GG had a 2.94 times greater risk of high TG levels than those who carried rs2710642AA and a 2.89 times greater risk than those who carried rs2710642AA + GA. Compared with those who carried rs2710642AA + GA, those who carried rs2710642GG were 2.53 times more likely to have low HDLC levels. The rs2710642–body mass index (BMI) (≥ 24 kg/m2) and rs11688816A–rs2710642G haplotype interactions increased the risk of dyslipidemia, and the rs2710642–BMI (≥ 24 kg/m2) interaction increased the risk of high TG levels. The rs10496099–rs2710642 and rs10496099–rs2710642–rs11688816 interactions increased the risk of low HDLC levels. Conclusions These results suggest that the EHBP1 rs2710642G and rs2710642GG and interactions with rs11688816A or BMI (≥ 24 kg/m2) were linked to higher dyslipidemia risks in end-stage renal disease patients in Chinese Han population.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2024) conducted a case-control in End-stage renal disease with dyslipidemia (n=539). EHBP1 rs2710642GG genotype vs. EHBP1 rs2710642AA genotype was evaluated on Risk of dyslipidemia (OR 2.72, 95% CI 1.17-6.35, p=0.04). The EHBP1 rs2710642GG genotype was associated with a 2.72-fold increased risk of dyslipidemia compared with the rs2710642AA genotype in Chinese Han patients with end-stage renal disease on dialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: